ASCO22: Breast cancer research by Chris Labaki, MD | Dana-Farber Cancer Institute

Dana-Farber's Chris Labaki, MD details how Real-World Progression-Free Survival and Time to Next Line of Therapy may be useful intermediate endpoints for survival in patients with advanced breast cancer. Research presented at #ASCO22